APTX:NSD-Aptinyx Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.42

Change

+0.07 (+2.09)%

Market Cap

USD 0.16B

Volume

0.19M

Average Target Price

USD 10.00 (+192.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.58 (+1.36%)

USD68.76B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+15.81 (+2.85%)

USD59.12B 21.90 16.92
SGEN Seattle Genetics, Inc

+3.12 (+1.74%)

USD31.48B N/A N/A
MRNA Moderna, Inc

-0.54 (-0.78%)

USD27.33B N/A N/A
GMAB Genmab A/S

-0.35 (-0.91%)

USD25.18B 27.12 3.06
BGNE BeiGene, Ltd

-2.27 (-0.84%)

USD25.05B N/A N/A
RPRX Royalty Pharma plc

+1.13 (+2.78%)

USD24.64B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.77 (+2.48%)

USD24.49B 30.43 27.52
IMMU Immunomedics, Inc

-0.36 (-0.42%)

USD19.70B N/A N/A
INCY Incyte Corporation

+1.54 (+1.80%)

USD18.67B 47.64 35.20

ETFs Containing APTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -12.76% 36% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.76% 36% F 42% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.06% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.06% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.70% N/A N/A N/A N/A
Risk Adjusted Return -62.19% N/A N/A N/A N/A
Market Capitalization 0.16B 35% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.38 88% B+ 64% D
Price / Cash Flow Ratio -3.02 34% F 69% D+
EV/EBITDA 0.14 70% C- 95% A
Management Effectiveness  
Return on Equity -46.04% 67% D+ 25% F
Return on Invested Capital -47.57% 65% D 20% F
Return on Assets -28.49% 47% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.75 46% F 35% F
Short Percent 3.62% 69% D+ 48% F
Beta 1.28 60% D- 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector